DE1001772T1 - Verbesserte verabreichungstechnik für multiple medikamentengaben - Google Patents
Verbesserte verabreichungstechnik für multiple medikamentengabenInfo
- Publication number
- DE1001772T1 DE1001772T1 DE1001772T DE98926529T DE1001772T1 DE 1001772 T1 DE1001772 T1 DE 1001772T1 DE 1001772 T DE1001772 T DE 1001772T DE 98926529 T DE98926529 T DE 98926529T DE 1001772 T1 DE1001772 T1 DE 1001772T1
- Authority
- DE
- Germany
- Prior art keywords
- dosage forms
- administration
- methylphenidate
- day
- technology
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4458—Non condensed piperidines, e.g. piperocaine only substituted in position 2, e.g. methylphenidate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
- A61K9/1676—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface having a drug-free core with discrete complete coating layer containing drug
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
- A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/34—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P17/00—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms
- C12P17/10—Nitrogen as only ring hetero atom
- C12P17/12—Nitrogen as only ring hetero atom containing a six-membered hetero ring
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P41/00—Processes using enzymes or microorganisms to separate optical isomers from a racemic mixture
- C12P41/006—Processes using enzymes or microorganisms to separate optical isomers from a racemic mixture by reactions involving C-N bonds, e.g. nitriles, amides, hydantoins, carbamates, lactames, transamination reactions, or keto group formation from racemic mixtures
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
- A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
- A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
- A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Wood Science & Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Zoology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Genetics & Genomics (AREA)
- Analytical Chemistry (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/892,190 US5837284A (en) | 1995-12-04 | 1997-07-14 | Delivery of multiple doses of medications |
PCT/US1998/012057 WO1999003471A1 (en) | 1997-07-14 | 1998-06-09 | Improved delivery of multiple doses of medications |
Publications (1)
Publication Number | Publication Date |
---|---|
DE1001772T1 true DE1001772T1 (de) | 2001-03-01 |
Family
ID=25399524
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE1001772T Pending DE1001772T1 (de) | 1997-07-14 | 1998-06-09 | Verbesserte verabreichungstechnik für multiple medikamentengaben |
DE69831869T Expired - Lifetime DE69831869T2 (de) | 1997-07-14 | 1998-06-09 | Verbesserte verabreichungstechnik für multiple medikamentengaben |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE69831869T Expired - Lifetime DE69831869T2 (de) | 1997-07-14 | 1998-06-09 | Verbesserte verabreichungstechnik für multiple medikamentengaben |
Country Status (11)
Country | Link |
---|---|
US (3) | US5837284A (de) |
EP (3) | EP1541147A1 (de) |
JP (2) | JP2002510318A (de) |
AT (1) | ATE306266T1 (de) |
AU (1) | AU738744B2 (de) |
CA (1) | CA2240329C (de) |
DE (2) | DE1001772T1 (de) |
DK (1) | DK1001772T3 (de) |
ES (1) | ES2153338T3 (de) |
HK (1) | HK1077501A1 (de) |
WO (1) | WO1999003471A1 (de) |
Families Citing this family (231)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6440457B1 (en) * | 1993-05-27 | 2002-08-27 | Alza Corporation | Method of administering antidepressant dosage form |
US5922736A (en) * | 1995-12-04 | 1999-07-13 | Celegene Corporation | Chronic, bolus administration of D-threo methylphenidate |
US6486177B2 (en) | 1995-12-04 | 2002-11-26 | Celgene Corporation | Methods for treatment of cognitive and menopausal disorders with D-threo methylphenidate |
US5837284A (en) * | 1995-12-04 | 1998-11-17 | Mehta; Atul M. | Delivery of multiple doses of medications |
US6355656B1 (en) * | 1995-12-04 | 2002-03-12 | Celgene Corporation | Phenidate drug formulations having diminished abuse potential |
US8071128B2 (en) | 1996-06-14 | 2011-12-06 | Kyowa Hakko Kirin Co., Ltd. | Intrabuccally rapidly disintegrating tablet and a production method of the tablets |
US6919373B1 (en) | 1996-11-12 | 2005-07-19 | Alza Corporation | Methods and devices for providing prolonged drug therapy |
US6962997B1 (en) * | 1997-05-22 | 2005-11-08 | Celgene Corporation | Process and intermediates for resolving piperidyl acetamide steroisomers |
US20040062802A1 (en) * | 1998-04-02 | 2004-04-01 | Hermelin Victor M. | Maximizing effectiveness of substances used to improve health and well being |
US5945123A (en) * | 1998-04-02 | 1999-08-31 | K-V Pharmaceutical Company | Maximizing effectiveness of substances used to improve health and well being |
DE69920689T2 (de) * | 1998-06-03 | 2005-02-24 | Alza Corp., Mountain View | Vorrichtungen zum Aufrechterhalten eines gewünschten therapeutischen Medikamenteneffekts über einen verlängerten Therapiezeitraum |
AU2004200325B2 (en) * | 1998-10-21 | 2006-09-28 | Shire Llc | Oral Pulsed Dose Drug Delivery System |
US20010055613A1 (en) * | 1998-10-21 | 2001-12-27 | Beth A. Burnside | Oral pulsed dose drug delivery system |
US20090149479A1 (en) * | 1998-11-02 | 2009-06-11 | Elan Pharma International Limited | Dosing regimen |
US20060240105A1 (en) * | 1998-11-02 | 2006-10-26 | Elan Corporation, Plc | Multiparticulate modified release composition |
US20080118556A1 (en) * | 1998-11-02 | 2008-05-22 | Elan Corporation, Plc | Modified Release of Compositions Containing a Combination of Carbidopa, Levodopa and Entacapone |
IL142896A0 (en) * | 1998-11-02 | 2002-04-21 | Elan Corp Plc | Multiparticulate modified release composition |
US6673367B1 (en) | 1998-12-17 | 2004-01-06 | Euro-Celtique, S.A. | Controlled/modified release oral methylphenidate formulations |
US6419960B1 (en) * | 1998-12-17 | 2002-07-16 | Euro-Celtique S.A. | Controlled release formulations having rapid onset and rapid decline of effective plasma drug concentrations |
US7083808B2 (en) * | 1998-12-17 | 2006-08-01 | Euro-Celtique S.A. | Controlled/modified release oral methylphenidate formulations |
US6127385A (en) * | 1999-03-04 | 2000-10-03 | Pharmaquest Limited | Method of treating depression using l-threo-methylphenidate |
US6395752B1 (en) * | 1999-03-04 | 2002-05-28 | Pharmaquest Limited | Method of treating depression using 1-threo-methylphenidate |
US20030170181A1 (en) * | 1999-04-06 | 2003-09-11 | Midha Kamal K. | Method for preventing abuse of methylphenidate |
CA2366791A1 (en) | 1999-04-06 | 2000-10-12 | Kamal K. Midha | Pharmaceutical dosage form for pulsatile delivery of d-threo-methylphenidate and a second cns stimulant |
US6368658B1 (en) | 1999-04-19 | 2002-04-09 | Scimed Life Systems, Inc. | Coating medical devices using air suspension |
US6730349B2 (en) | 1999-04-19 | 2004-05-04 | Scimed Life Systems, Inc. | Mechanical and acoustical suspension coating of medical implants |
GB9913458D0 (en) * | 1999-06-09 | 1999-08-11 | Medeva Europ Ltd | The therapeutic use of d-threo-methylphenidate |
EP1064937A1 (de) * | 1999-06-28 | 2001-01-03 | Sanofi-Synthelabo | Pharmazeutische Zusammensetzungen mit kontrollierten Freigabe enthaltend ein Hypnotikum mit kurzer Wirkung oder deren Salze |
US10179130B2 (en) | 1999-10-29 | 2019-01-15 | Purdue Pharma L.P. | Controlled release hydrocodone formulations |
RU2230556C2 (ru) | 1999-10-29 | 2004-06-20 | Эро-Селтик, С.А. | Препаративные формы гидрокодона с контролируемым высвобождением |
AU2001231018A1 (en) | 2000-01-19 | 2001-07-31 | Pharmaceutical Discovery Corporation | Multi-spike release formulation for drug delivery |
US6627223B2 (en) | 2000-02-11 | 2003-09-30 | Eurand Pharmaceuticals Ltd. | Timed pulsatile drug delivery systems |
US6544555B2 (en) | 2000-02-24 | 2003-04-08 | Advancis Pharmaceutical Corp. | Antibiotic product, use and formulation thereof |
US7674480B2 (en) * | 2000-06-23 | 2010-03-09 | Teva Pharmaceutical Industries Ltd. | Rapidly expanding composition for gastric retention and controlled release of therapeutic agents, and dosage forms including the composition |
US6881420B2 (en) * | 2000-06-23 | 2005-04-19 | Teva Pharmaceutical Industries Ltd. | Compositions and dosage forms for gastric delivery of irinotecan and methods of treatment that use it to inhibit cancer cell proliferation |
US6476006B2 (en) | 2000-06-23 | 2002-11-05 | Teva Pharmaceutical Industries, Ltd. | Composition and dosage form for delayed gastric release of alendronate and/or other bis-phosphonates |
US6500457B1 (en) | 2000-08-14 | 2002-12-31 | Peirce Management, Llc | Oral pharmaceutical dosage forms for pulsatile delivery of an antiarrhythmic agent |
US20020068078A1 (en) | 2000-10-13 | 2002-06-06 | Rudnic Edward M. | Antifungal product, use and formulation thereof |
US6344215B1 (en) * | 2000-10-27 | 2002-02-05 | Eurand America, Inc. | Methylphenidate modified release formulations |
AU2002227383B2 (en) | 2000-10-30 | 2004-07-08 | Euro-Celtique S.A. | Controlled release hydrocodone formulations |
CA2431205C (en) * | 2000-12-05 | 2005-08-23 | Alexander Macgregor | Hydrostatic delivery system for controlled delivery of agent |
CA2440641A1 (en) | 2001-03-13 | 2002-09-19 | Anand R. Baichwal | Chronotherapeutic dosage forms containing glucocorticosteroid |
US20020187192A1 (en) * | 2001-04-30 | 2002-12-12 | Yatindra Joshi | Pharmaceutical composition which reduces or eliminates drug abuse potential |
US20030049272A1 (en) * | 2001-08-30 | 2003-03-13 | Yatindra Joshi | Pharmaceutical composition which produces irritation |
US6500454B1 (en) * | 2001-10-04 | 2002-12-31 | Eurand Pharmaceuticals Ltd. | Timed, sustained release systems for propranolol |
US9358214B2 (en) | 2001-10-04 | 2016-06-07 | Adare Pharmaceuticals, Inc. | Timed, sustained release systems for propranolol |
US20050025824A1 (en) * | 2001-12-14 | 2005-02-03 | Eurand Pharmaceuticals Ltd. | Pulsatile release histamine H2 antagonist dosage form |
US6663888B2 (en) | 2001-12-14 | 2003-12-16 | Eurand Pharmaceuticals Ltd. | Pulsatile release histamine H2 antagonist dosage form |
US6638533B2 (en) | 2002-01-03 | 2003-10-28 | George Krsek | Pulse dosage formulations of methylphenidate and method to prepare same |
US20030165614A1 (en) * | 2002-03-01 | 2003-09-04 | Henrik Hansen | Coating a medical implant using a pan coater |
US20050232995A1 (en) | 2002-07-29 | 2005-10-20 | Yam Nyomi V | Methods and dosage forms for controlled delivery of paliperidone and risperidone |
CA2395819A1 (en) * | 2002-08-13 | 2004-02-13 | Bernard Charles Sherman | Dual-spike release formulation for oral drug delivery |
US20060039974A1 (en) | 2002-09-11 | 2006-02-23 | Takeda Pharmaceutical Company Limited | Sustained release preparation |
US6913768B2 (en) * | 2002-09-24 | 2005-07-05 | Shire Laboratories, Inc. | Sustained release delivery of amphetamine salts |
US20080220074A1 (en) * | 2002-10-04 | 2008-09-11 | Elan Corporation Plc | Gamma radiation sterilized nanoparticulate docetaxel compositions and methods of making same |
US20040109889A1 (en) * | 2002-12-04 | 2004-06-10 | Bunick Frank J. | Surface treatment composition for soft substrates |
US7988993B2 (en) * | 2002-12-09 | 2011-08-02 | Andrx Pharmaceuticals, Inc. | Oral controlled release dosage form |
SI1575569T1 (sl) | 2002-12-13 | 2010-12-31 | Durect Corp | Oralni sistem dostave zdravila, ki obsega visokoviskozne tekoče nosilne materiale |
US8367111B2 (en) | 2002-12-31 | 2013-02-05 | Aptalis Pharmatech, Inc. | Extended release dosage forms of propranolol hydrochloride |
WO2005009364A2 (en) | 2003-07-21 | 2005-02-03 | Advancis Pharmaceutical Corporation | Antibiotic product, use and formulation thereof |
WO2005009365A2 (en) | 2003-07-21 | 2005-02-03 | Advancis Pharmaceutical Corporation | Antibiotic product, use and formulation thereof |
WO2005009368A2 (en) | 2003-07-21 | 2005-02-03 | Advancis Pharmaceutical Corporation | Antibiotic product, use and formulation thereof |
WO2005016311A1 (en) | 2003-08-11 | 2005-02-24 | Advancis Pharmaceutical Corporation | Robust pellet |
AU2004264356B2 (en) | 2003-08-12 | 2011-01-27 | Shionogi, Inc. | Antibiotic product, use and formulation thereof |
WO2005023184A2 (en) * | 2003-08-29 | 2005-03-17 | Advancis Pharmaceuticals Corporation | Antibiotic product, use and formulation thereof |
CA2537477C (en) * | 2003-09-03 | 2013-05-14 | Boehringer Ingelheim International Gmbh | Capsules containing active substance pellets with different release profiles |
WO2005027877A1 (en) | 2003-09-15 | 2005-03-31 | Advancis Pharmaceutical Corporation | Antibiotic product, use and formulation thereof |
NZ545921A (en) | 2003-09-19 | 2009-09-25 | Penwest Pharmaceuticals Co | Delayed released dosage forms |
US20090304793A1 (en) * | 2003-09-22 | 2009-12-10 | Alpharma, Inc. | Sustained release opioid formulations and methods of use |
US20050187196A1 (en) * | 2004-02-23 | 2005-08-25 | Saegis Pharmaceuticals, Inc. | Treatment of attention disorders |
US7404970B2 (en) * | 2004-04-13 | 2008-07-29 | Konec, Inc. | Pain relief composition, method to form same, and method to use same |
US20050239830A1 (en) * | 2004-04-26 | 2005-10-27 | Vikram Khetani | Methods of diminishing co-abuse potential |
ES2261006B1 (es) | 2004-06-10 | 2007-11-01 | Laboratorios Rubio, S.A. | Pellet multicapa de liberacion controlada de metilfenidato. |
EP1768668A2 (de) | 2004-06-16 | 2007-04-04 | Tap Pharmaceutical Products, Inc. | Multi-ppi-dosierform |
WO2006014427A1 (en) | 2004-07-02 | 2006-02-09 | Advancis Pharmaceutical Corporation | Tablet for pulsed delivery |
WO2006012536A2 (en) | 2004-07-22 | 2006-02-02 | Ritter Andrew J | Methods and compositions for treating lactose intolerance |
DK2036546T3 (en) * | 2004-08-23 | 2018-12-17 | Pejo Iserlohn Heilmittel Und Diaet Gmbh & Co Kg | Psychostimulants containing a pharmaceutical composition |
US8747895B2 (en) | 2004-09-13 | 2014-06-10 | Aptalis Pharmatech, Inc. | Orally disintegrating tablets of atomoxetine |
US9884014B2 (en) | 2004-10-12 | 2018-02-06 | Adare Pharmaceuticals, Inc. | Taste-masked pharmaceutical compositions |
CA2584957C (en) | 2004-10-21 | 2015-08-25 | Eurand Pharmaceuticals Limited | Taste-masked pharmaceutical compositions with gastrosoluble pore-formers |
WO2006063078A2 (en) * | 2004-12-08 | 2006-06-15 | Elan Corporation, Plc | Topiramate pharmaceuticals composition |
CA2591247A1 (en) * | 2004-12-09 | 2006-06-15 | Celgene Corporation | Treatment of patients suffering from a disease having a family history or diagnosis of tics or tourette's syndrome with d-threo methylphenidate |
GB0507298D0 (en) | 2005-04-11 | 2005-05-18 | Novartis Ag | Organic compounds |
MX2007012763A (es) * | 2005-04-12 | 2008-01-14 | Elan Pharma Int Ltd | Composiciones de liberacion controlada que comprenden una cefalosporina para el tratamiento de infeccion bacteriana. |
US9161918B2 (en) | 2005-05-02 | 2015-10-20 | Adare Pharmaceuticals, Inc. | Timed, pulsatile release systems |
WO2007070082A1 (en) * | 2005-05-10 | 2007-06-21 | Elan Pharma International Limited | Nanoparticulate and controlled release compositions comprising teprenone |
WO2007037790A2 (en) * | 2005-06-08 | 2007-04-05 | Elan Corporation, Plc | Modified release famciclovir compositions |
EP2502621A1 (de) | 2005-06-27 | 2012-09-26 | Valeant International (Barbados) SRL | Kristalline Formen von Bupropion HBr |
WO2007038686A2 (en) | 2005-09-27 | 2007-04-05 | Tissuetech, Inc. | Amniotic membrane preparations and purified compositions and methods of use |
US8187639B2 (en) | 2005-09-27 | 2012-05-29 | Tissue Tech, Inc. | Amniotic membrane preparations and purified compositions and anti-angiogenesis treatment |
WO2007132293A2 (en) * | 2005-11-10 | 2007-11-22 | Circ Pharma Research And Development Limited | Once-daily administration of central nervous system drugs |
AU2006318349B2 (en) | 2005-11-28 | 2010-08-19 | Marinus Pharmaceuticals | Ganaxolone formulations and methods for the making and use thereof |
US8778924B2 (en) | 2006-12-04 | 2014-07-15 | Shionogi Inc. | Modified release amoxicillin products |
US8357394B2 (en) | 2005-12-08 | 2013-01-22 | Shionogi Inc. | Compositions and methods for improved efficacy of penicillin-type antibiotics |
RU2428176C2 (ru) * | 2006-01-27 | 2011-09-10 | Юранд, Инк. | Системы доставки лекарственного средства, содержащие слабоосновные лекарственные средства и органические кислоты |
KR101413613B1 (ko) * | 2006-01-27 | 2014-07-10 | 앱탈리스 파마테크, 인코포레이티드 | 약 염기성 선택성 세로토닌 5-ht3 차단제와 유기산을 포함하는 약물 전달 시스템 |
RU2435569C2 (ru) | 2006-03-16 | 2011-12-10 | Трис Фарма, Инк. | Композиции с модифицированным высвобождением, содержащие комплексы лекарственное вещество - ионообменная смола |
US8299052B2 (en) | 2006-05-05 | 2012-10-30 | Shionogi Inc. | Pharmaceutical compositions and methods for improved bacterial eradication |
US8846100B2 (en) | 2006-05-12 | 2014-09-30 | Shire Llc | Controlled dose drug delivery system |
EP2056818B1 (de) | 2006-08-11 | 2011-05-25 | The Johns Hopkins University | Zusammensetzungen und verfahren für nervenschutz |
PT2526933E (pt) | 2006-09-22 | 2015-06-23 | Pharmacyclics Inc | Inibidores da tirosina-quinase de bruton |
JP2010522135A (ja) | 2006-10-09 | 2010-07-01 | チャールストン ラボラトリーズ,インコーポレイテッド | 医薬組成物 |
AU2007319141B2 (en) | 2006-11-17 | 2013-01-10 | Supernus Pharmaceuticals Inc. | Sustained-release formulations of topiramate |
WO2008082856A1 (en) | 2006-12-26 | 2008-07-10 | Pharmacyclics, Inc. | Method of using histone deacetylase inhibitors and monitoring biomarkers in combination therapy |
CN101730467A (zh) * | 2007-07-06 | 2010-06-09 | 努恩治疗学股份有限公司 | 神经病性疼痛的治疗 |
CN101854933A (zh) | 2007-09-10 | 2010-10-06 | 钙医学公司 | 调节细胞内钙的化合物 |
KR20170097787A (ko) | 2007-10-12 | 2017-08-28 | 다케다 파마슈티칼스 유에스에이, 인코포레이티드 | 음식 섭취와 관계없이 위장 장애를 치료하는 방법 |
CA2706931C (en) | 2007-12-06 | 2015-05-12 | Durect Corporation | Oral pharmaceutical dosage forms |
EP2240022B1 (de) | 2008-01-09 | 2016-12-28 | Charleston Laboratories, Inc. | Oxycodone und Promethazine enthaltende zweischichtige Tabletten |
CA2627198A1 (en) * | 2008-03-27 | 2009-09-27 | Pharmascience Inc. | Methylphenidate extended release therapeutic drug delivery system |
US20090311335A1 (en) * | 2008-06-12 | 2009-12-17 | Scott Jenkins | Combination of a triptan and an nsaid |
US20100034967A1 (en) * | 2008-08-07 | 2010-02-11 | Vector Corporation | Dry polymer layering using a rotor processor |
US20100034968A1 (en) * | 2008-08-07 | 2010-02-11 | Vector Corporation | Polymer coating process using dry glidant in a rotor processor |
US8807070B2 (en) * | 2008-08-07 | 2014-08-19 | Vector Corporation | Rotor processor for dry powders |
KR101724161B1 (ko) | 2008-08-27 | 2017-04-06 | 칼시메디카, 인크 | 세포내 칼슘을 조절하는 화합물 |
US20100260844A1 (en) | 2008-11-03 | 2010-10-14 | Scicinski Jan J | Oral pharmaceutical dosage forms |
KR101264961B1 (ko) * | 2008-11-07 | 2013-05-16 | 주식회사 삼양바이오팜 | 메칠페니데이트의 방출 제어용 약제학적 조성물 |
WO2010071866A2 (en) | 2008-12-19 | 2010-06-24 | Nuon Therapeutics, Inc. | Combination therapy for arthritis with tranilast |
SG2014014435A (en) | 2009-02-24 | 2014-07-30 | Ritter Pharmaceuticals Inc | Prebiotic formulations and methods of use |
US20100227876A1 (en) * | 2009-03-06 | 2010-09-09 | Rechfensen Llp | Methods of Reducing Side Effects of Analgesics |
US8603521B2 (en) | 2009-04-17 | 2013-12-10 | Pharmacyclics, Inc. | Formulations of histone deacetylase inhibitor and uses thereof |
ES2559029T3 (es) | 2009-04-24 | 2016-02-10 | Tissue Tech, Inc. | Composiciones que contienen al complejo HC.HA y metodos de uso de las mismas |
US20110003005A1 (en) * | 2009-07-06 | 2011-01-06 | Gopi Venkatesh | Methods of Treating PDNV and PONV with Extended Release Ondansetron Compositions |
CA2767576C (en) | 2009-07-08 | 2020-03-10 | Charleston Laboratories Inc. | Pharmaceutical compositions comprising an antiemetic and an opioid analgesic |
EP2462128B1 (de) | 2009-08-04 | 2016-09-21 | Amira Pharmaceuticals, Inc. | Verbindungen als lysophosphatidsäure-rezeptorantagonisten |
WO2011020032A2 (en) * | 2009-08-13 | 2011-02-17 | Kudco Ireland, Ltd. | Pharmaceutical dosage form |
GB2474120B (en) | 2009-10-01 | 2011-12-21 | Amira Pharmaceuticals Inc | Compounds as Lysophosphatidic acid receptor antagonists |
US7718662B1 (en) | 2009-10-12 | 2010-05-18 | Pharmacyclics, Inc. | Pyrazolo-pyrimidine inhibitors of bruton's tyrosine kinase |
SG10201407965XA (en) | 2009-12-02 | 2015-02-27 | Aptalis Pharma Ltd | Fexofenadine microcapsules and compositions containing them |
EP3124481B1 (de) | 2010-02-16 | 2018-03-28 | Aragon Pharmaceuticals, Inc. | Androgenrezeptormodulatoren und verwendungen davon |
EP2558866B1 (de) | 2010-04-15 | 2016-08-17 | Tracon Pharmaceuticals, Inc. | Potenzierung einer antikrebs-wirkung durch eine kombinationstherapie mit ber-pfad-hemmern |
AU2011248877B9 (en) | 2010-04-27 | 2015-11-05 | Calcimedica Inc. | Compounds that modulate intracellular calcium |
AU2011248579A1 (en) | 2010-04-27 | 2012-11-29 | Calcimedica, Inc. | Compounds that modulate intracellular calcium |
WO2011137249A1 (en) | 2010-04-28 | 2011-11-03 | Ritter Pharmaceuticals, Inc. | Prebiotic formulations and methods of use |
EP2568999B1 (de) | 2010-05-11 | 2018-07-11 | Mallinckrodt Ard Ip Limited | Acth zur behandlung von amyotropher lateralsklerose |
PL2580210T3 (pl) | 2010-06-10 | 2017-09-29 | Seragon Pharmaceuticals, Inc. | Modulatory receptora estrogenowego i ich zastosowania |
MX337711B (es) | 2010-08-27 | 2016-03-15 | Calcimedica Inc | Compuestos que modulan el calcio intracelular. |
US8796416B1 (en) | 2010-10-25 | 2014-08-05 | Questcor Pharmaceuticals, Inc | ACTH prophylactic treatment of renal disorders |
BR112013014019A2 (pt) | 2010-12-07 | 2016-09-13 | Amira Pharmaceuticals Inc | antagonistas do receptor do ácido lisofosfatídico e seus usos |
US8287903B2 (en) | 2011-02-15 | 2012-10-16 | Tris Pharma Inc | Orally effective methylphenidate extended release powder and aqueous suspension product |
EP2675434A1 (de) * | 2011-02-17 | 2013-12-25 | F.Hoffmann-La Roche Ag | Verfahren zur kontrollierten kristallisierung eines wirkstoffes aus einem unterkühlten flüssigkeitszustand durch schmelzextrusion |
US9283214B2 (en) | 2011-03-23 | 2016-03-15 | Ironshore Pharmaceuticals & Development, Inc. | Compositions for treatment of attention deficit hyperactivity disorder |
US9119809B2 (en) | 2011-03-23 | 2015-09-01 | Ironshore Pharmaceuticals & Development, Inc. | Compositions for treatment of attention deficit hyperactivity disorder |
US10292937B2 (en) | 2011-03-23 | 2019-05-21 | Ironshore Pharmaceuticals & Development, Inc. | Methods of treatment of attention deficit hyperactivity disorder |
US10905652B2 (en) | 2011-03-23 | 2021-02-02 | Ironshore Pharmaceuticals & Development, Inc. | Compositions for treatment of attention deficit hyperactivity disorder |
EP4011364B1 (de) * | 2011-03-23 | 2023-12-13 | Ironshore Pharmaceuticals & Development, Inc. | Verfahren und zusammensetzungen zur behandlung von aufmerksamkeitsdefizitsyndrom |
US8927010B2 (en) | 2011-03-23 | 2015-01-06 | Ironshore Pharmaceuticals & Development, Inc. | Compositions for treatment of attention deficit hyperactivity disorder |
US9603809B2 (en) | 2011-03-23 | 2017-03-28 | Ironshore Pharmaceuticals & Development, Inc. | Methods of treatment of attention deficit hyperactivity disorder |
US11241391B2 (en) | 2011-03-23 | 2022-02-08 | Ironshore Pharmaceuticals & Development, Inc. | Compositions for treatment of attention deficit hyperactivity disorder |
US9498447B2 (en) | 2011-03-23 | 2016-11-22 | Ironshore Pharmaceuticals & Development, Inc. | Compositions for treatment of attention deficit hyperactivity disorder |
US8916588B2 (en) | 2011-03-23 | 2014-12-23 | Ironshore Pharmaceuticals & Development, Inc. | Methods for treatment of attention deficit hyperactivity disorder |
WO2012149486A1 (en) | 2011-04-28 | 2012-11-01 | Tissuetech, Inc. | Methods of modulating bone remodeling |
WO2012166415A1 (en) | 2011-05-27 | 2012-12-06 | Amira Pharmaceuticals, Inc. | Heterocyclic autotaxin inhibitors and uses thereof |
WO2012170905A1 (en) | 2011-06-10 | 2012-12-13 | Tissuetech, Inc. | Methods of processing fetal support tissues, fetal support tissue powder products, and uses thereof |
WO2013003622A1 (en) | 2011-06-28 | 2013-01-03 | Neos Therapeutics, Lp | Dosage forms for oral administration and methods of treatment using the same |
ES2627820T3 (es) | 2011-09-13 | 2017-07-31 | Pharmacyclics, Inc. | Formulaciones de inhibidor de histona desacetilasa en combinación con bendamustina y usos de las mismas |
US8377946B1 (en) | 2011-12-30 | 2013-02-19 | Pharmacyclics, Inc. | Pyrazolo[3,4-d]pyrimidine and pyrrolo[2,3-d]pyrimidine compounds as kinase inhibitors |
NZ630124A (en) | 2012-03-20 | 2016-01-29 | Seragon Pharmaceuticals Inc | Estrogen receptor modulators and uses thereof |
EP2872181B1 (de) | 2012-07-11 | 2020-11-18 | Tissuetech, Inc. | Zusammensetzungen mit hc-ha/ptx3-komplexen und verfahren zur verwendung davon |
AR091857A1 (es) | 2012-07-25 | 2015-03-04 | Sova Pharmaceuticals Inc | INHIBIDORES DE CISTATIONIN-g-LIASA (CSE) |
AR091858A1 (es) | 2012-07-25 | 2015-03-04 | Sova Pharmaceuticals Inc | INHIBIDORES DE CISTATIONIN-g-LIASA (CSE) |
BR112015003120B1 (pt) | 2012-08-15 | 2022-08-09 | Tris Pharma , Inc | Tablete mastigável de liberação estendida de metilfenidato e seu uso |
SG10201912719TA (en) | 2012-09-26 | 2020-02-27 | Aragon Pharmaceuticals Inc | Anti-androgens for the treatment of non-metastatic castrate-resistant prostate cancer |
EP2900674B1 (de) | 2012-09-28 | 2017-05-31 | University of Washington through its Center for Commercialization | Verbindungen und verfahren zur vorbeugung, behandlung und/oder schutz vor haarzelltod |
US9512116B2 (en) | 2012-10-12 | 2016-12-06 | Calcimedica, Inc. | Compounds that modulate intracellular calcium |
ES2821528T3 (es) | 2012-11-14 | 2021-04-26 | Grace W R & Co | Composiciones que contienen un material biológicamente activo y un óxido inorgánico no ordenado |
JOP20200097A1 (ar) | 2013-01-15 | 2017-06-16 | Aragon Pharmaceuticals Inc | معدل مستقبل أندروجين واستخداماته |
EP2968475A2 (de) | 2013-03-14 | 2016-01-20 | Questcor Pharmaceuticals, Inc. | Acth zur behandlung des akuten atemstresssyndroms |
EP2983468A4 (de) | 2013-03-15 | 2016-09-07 | Durect Corp | Zusammensetzungen mit rheologiemodifikator zur reduzierung der auflösungsvariabilität |
BR112015020261A2 (pt) | 2013-03-29 | 2017-07-18 | Wockhardt Ltd | composições farmacêuticas de dexmetilfenidato ou sais do mesmo de liberação modificada |
WO2014174388A1 (en) * | 2013-03-29 | 2014-10-30 | Wockhardt Limited | Modified release pharmaceutical compositions of methylphenidate or salts thereof |
MX2015016171A (es) | 2013-06-19 | 2016-08-08 | Seragon Pharmaceuticals Inc | Moduladores del receptor de estrogeno de azetidina y usos de los mismos. |
BR112015031903A8 (pt) | 2013-06-19 | 2019-12-31 | Seragon Pharmaceuticals Inc | composto, sal farmaceuticamente aceitável, composição farmacêutica e uso de um composto |
US9611263B2 (en) | 2013-10-08 | 2017-04-04 | Calcimedica, Inc. | Compounds that modulate intracellular calcium |
EP3077388A1 (de) | 2013-12-05 | 2016-10-12 | Pharmacyclics, LLC | Hemmer der bruton-tyrosinkinase |
WO2015148538A1 (en) * | 2014-03-24 | 2015-10-01 | Kashiv Pharma, Llc | Method of manufacturing fine particles suitable for orally disintegrating pharmaceutical dosage forms |
US20170216328A1 (en) | 2014-04-04 | 2017-08-03 | Ritter Pharmaceuticals, Inc. | Methods and compositions for microbiome alteration |
TW201603818A (zh) | 2014-06-03 | 2016-02-01 | 組織科技股份有限公司 | 組成物及方法 |
US9839644B2 (en) | 2014-09-09 | 2017-12-12 | ARKAY Therapeutics, LLC | Formulations and methods for treatment of metabolic syndrome |
CA2936746C (en) | 2014-10-31 | 2017-06-27 | Purdue Pharma | Methods and compositions particularly for treatment of attention deficit disorder |
US9359316B1 (en) | 2014-11-25 | 2016-06-07 | Concentric Analgesics, Inc. | Prodrugs of phenolic TRPV1 agonists |
US10399994B2 (en) | 2015-02-06 | 2019-09-03 | University Of Washington | Compounds and methods for preventing or treating sensory hair cell death |
US10227333B2 (en) | 2015-02-11 | 2019-03-12 | Curtana Pharmaceuticals, Inc. | Inhibition of OLIG2 activity |
WO2016138025A2 (en) | 2015-02-23 | 2016-09-01 | Tissuetech, Inc. | Apparatuses and methods for treating ophthalmic diseases and disorders |
CN107530304A (zh) | 2015-02-27 | 2018-01-02 | 科泰纳制药公司 | Olig2活性的抑制 |
US10342831B2 (en) | 2015-05-20 | 2019-07-09 | Tissuetech, Inc. | Composition and methods for preventing the proliferation and epithelial-mesenchymal transition of epithelial cells |
US11590228B1 (en) | 2015-09-08 | 2023-02-28 | Tris Pharma, Inc | Extended release amphetamine compositions |
WO2017074957A1 (en) | 2015-10-26 | 2017-05-04 | MAX BioPharma, Inc. | Oxysterols and hedgehog signaling |
US9637514B1 (en) | 2015-10-26 | 2017-05-02 | MAX BioPharma, Inc. | Oxysterols and hedgehog signaling |
EP4253412A3 (de) | 2015-12-16 | 2023-11-22 | The Walter and Eliza Hall Institute of Medical Research | Hemmung von cytokininduziertem sh2-protein in nk-zellen |
TWI726969B (zh) | 2016-01-11 | 2021-05-11 | 比利時商健生藥品公司 | 用作雄性激素受體拮抗劑之經取代之硫尿囊素衍生物 |
TW201733600A (zh) | 2016-01-29 | 2017-10-01 | 帝聖工業公司 | 胎兒扶持組織物及使用方法 |
JP2019507181A (ja) | 2016-03-04 | 2019-03-14 | チャールストン ラボラトリーズ,インコーポレイテッド | 医薬組成物 |
WO2017205534A1 (en) | 2016-05-25 | 2017-11-30 | Concentric Analgesics, Inc. | Prodrugs of phenolic trpv1 agonists in combination with local anesthetics and vasoconstrictors for improved local anesthesia |
WO2017205769A1 (en) | 2016-05-27 | 2017-11-30 | Pharmacyclics Llc | Inhibitors of interleukin-1 receptor-associated kinase |
WO2017205766A1 (en) | 2016-05-27 | 2017-11-30 | Pharmacyclics Llc | Inhibitors of interleukin-1 receptor-associated kinase |
WO2017205762A1 (en) | 2016-05-27 | 2017-11-30 | Pharmacyclics Llc | Inhibitors of interleukin-1 receptor-associated kinase |
CA3035123A1 (en) | 2016-08-26 | 2018-03-01 | Curtana Pharmaceuticals, Inc. | Inhibition of olig2 activity |
EP4364802A3 (de) | 2016-12-11 | 2024-07-03 | Zevra Therapeutics, Inc. | Zusammensetzungen mit methylphenidat-prodrugs, verfahren zur herstellung und verwendung davon |
EP3372225A1 (de) | 2017-03-09 | 2018-09-12 | Develco Pharma Schweiz AG | Neuartige darreichungsform |
US11590081B1 (en) | 2017-09-24 | 2023-02-28 | Tris Pharma, Inc | Extended release amphetamine tablets |
AU2018351714A1 (en) | 2017-10-16 | 2020-04-30 | Aragon Pharmaceuticals, Inc. | Anti-androgens for the treatment of non-metastatic castration-resistant prostate cancer |
US11319320B2 (en) | 2017-11-06 | 2022-05-03 | Snap Bio, Inc. | PIM kinase inhibitor compositions, methods, and uses thereof |
WO2019118984A2 (en) | 2017-12-15 | 2019-06-20 | Solarea Bio, Inc. | Microbial compositions and methods for treating type 2 diabetes, obesity, and metabolic syndrome |
US11685722B2 (en) | 2018-02-28 | 2023-06-27 | Curtana Pharmaceuticals, Inc. | Inhibition of Olig2 activity |
CN112368301A (zh) | 2018-04-30 | 2021-02-12 | 西达-赛奈医疗中心 | 用于选择和治疗炎性疾病患者的方法和系统 |
TW202019887A (zh) | 2018-07-27 | 2020-06-01 | 美商同心止痛劑股份有限公司 | 酚系trpv1促效劑之聚乙二醇化前藥 |
EP3846830A4 (de) | 2018-09-05 | 2022-07-06 | Solarea Bio, Inc. | Verfahren und zusammensetzungen zur behandlung von muskel-skelett-erkrankungen |
US11980647B2 (en) | 2018-09-05 | 2024-05-14 | Solarea Bio, Inc. | Methods and compositions for treating musculoskeletal diseases, treating inflammation, and managing symptoms of menopause |
US10722473B2 (en) | 2018-11-19 | 2020-07-28 | Purdue Pharma L.P. | Methods and compositions particularly for treatment of attention deficit disorder |
JP2022516057A (ja) | 2018-12-31 | 2022-02-24 | バイオメア フュージョン,エルエルシー | メニン-mll相互作用の不可逆的阻害剤 |
EP3937938A1 (de) | 2019-03-15 | 2022-01-19 | Unicycive Therapeutics Inc. | Nicorandilderivate |
EP3946547A4 (de) | 2019-03-26 | 2023-01-18 | Pocket Naloxone Corp. | Vorrichtungen und verfahren zur abgabe von pharmazeutischen zusammensetzungen |
KR20220088529A (ko) | 2019-05-14 | 2022-06-27 | 프로메테우스 바이오사이언시즈, 인크. | Tl1a 환자 선택 방법, 시스템 및 장치 |
WO2020257722A2 (en) | 2019-06-19 | 2020-12-24 | Solarea Bio, Inc. | Microbial compositions and methods for producing upgraded probiotic assemblages |
MA56541A (fr) | 2019-06-21 | 2022-04-27 | Entelexo Biotherapeutics Inc | Plateformes, compositions et méthodes d'administration de composés thérapeutiques |
EP4263542A1 (de) | 2020-12-16 | 2023-10-25 | Biomea Fusion, Inc. | Kondensierte pyrimidinverbindungen als inhibitoren der menin-mll-interaktion |
CA3204457A1 (en) | 2021-01-06 | 2022-07-14 | Ben SESSA | Mdma in the treatment of alcohol use disorder |
US11278709B1 (en) | 2021-03-12 | 2022-03-22 | Pocket Naloxone Corp. | Drug delivery device and methods for using same |
WO2022238507A1 (en) | 2021-05-11 | 2022-11-17 | Awakn Ls Europe Holdings Limited | Therapeutic aminoindane compounds and compositions |
WO2022256720A2 (en) | 2021-06-03 | 2022-12-08 | Arcadia Medicine, Inc. | Enantiomeric entactogen compositions and methods of their use |
AU2022325861A1 (en) | 2021-08-11 | 2024-02-29 | Biomea Fusion, Inc. | Covalent inhibitors of menin-mll interaction for diabetes mellitus |
WO2023027966A1 (en) | 2021-08-24 | 2023-03-02 | Biomea Fusion, Inc. | Pyrazine compounds as irreversible inhibitors of flt3 |
WO2023039240A1 (en) | 2021-09-13 | 2023-03-16 | Biomea Fusion, Inc. | IRREVERSIBLE INHIBITORS OF KRas |
WO2023086341A1 (en) | 2021-11-09 | 2023-05-19 | Biomea Fusion, Inc. | Inhibitors of kras |
WO2023092150A1 (en) | 2021-11-22 | 2023-05-25 | Solarea Bio, Inc. | Methods and compositions for treating musculoskeletal diseases, treating inflammation, and managing symptoms of menopause |
US20230190834A1 (en) | 2021-12-21 | 2023-06-22 | Solarea Bio, Inc. | Immunomodulatory compositions comprising microbial entities |
US11945785B2 (en) | 2021-12-30 | 2024-04-02 | Biomea Fusion, Inc. | Pyrazine compounds as inhibitors of FLT3 |
WO2023139163A1 (en) | 2022-01-19 | 2023-07-27 | Awakn Ls Europe Holdings Limited | 1,3-benzodioxole esters and their therapeutic use |
WO2023156565A1 (en) | 2022-02-16 | 2023-08-24 | Awakn Ls Europe Holdings Limited | Bridged ring compounds and their therapeutic use as cns agents |
WO2023235618A1 (en) | 2022-06-03 | 2023-12-07 | Biomea Fusion, Inc. | Fused pyrimidine compounds as inhibitors of menin |
Family Cites Families (95)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2507631A (en) | 1944-01-19 | 1950-05-16 | Ciba Pharm Prod Inc | Pyridine and piperidine compounds and process of making same |
GB589625A (en) | 1944-01-19 | 1947-06-25 | Chem Ind Basel | Manufacture of new pyridine and piperidine compounds |
US2838519A (en) * | 1953-12-23 | 1958-06-10 | Ciba Pharm Prod Inc | Process for the conversion of stereoisomers |
US2957880A (en) | 1953-12-23 | 1960-10-25 | Ciba Pharm Prod Inc | Process for the conversion of stereoisomers |
GB788226A (en) | 1953-12-23 | 1957-12-23 | Ciba Ltd | Stereoisomers of ª‡-phenyl-ª‡-piperidyl-(2)-acetic acid and process of making same |
GB878167A (en) | 1958-11-17 | 1961-09-27 | Ciba Ltd | New acetic acid esters |
SU466229A1 (ru) | 1973-01-23 | 1975-04-05 | Всесоюзный научно-исследовательский химико-фармацевтический институт им. С.Орджоникидзе | Способ получени гидрохлорида метилового эфира трео- -фенил- (пиперидил-2)-уксусной кислоты |
DE2322883A1 (de) | 1973-05-07 | 1974-11-28 | Roehm Gmbh | Wasserloesliche polymerisate |
US4137300A (en) | 1976-08-20 | 1979-01-30 | Ciba-Geigy Corporation | Sustained action dosage forms |
US4410700A (en) * | 1980-07-03 | 1983-10-18 | The United States Of America As Represented By The Department Of Health And Human Services | Preparation of chiral 1-benzyl-1,2,3,4-tetrahydroisoquinolines by optical resolution |
DE3279999D1 (en) * | 1981-09-30 | 1989-11-30 | Nat Res Dev | Compositions comprising encapsulated particles |
US4904476A (en) * | 1986-03-04 | 1990-02-27 | American Home Products Corporation | Formulations providing three distinct releases |
US4794001A (en) * | 1986-03-04 | 1988-12-27 | American Home Products Corporation | Formulations providing three distinct releases |
US4842867A (en) | 1986-05-09 | 1989-06-27 | Alza Corporation | Pulsed drug delivery of doxylamine |
US4986987A (en) * | 1986-05-09 | 1991-01-22 | Alza Corporation | Pulsed drug delivery |
US5114946A (en) | 1987-06-12 | 1992-05-19 | American Cyanamid Company | Transdermal delivery of pharmaceuticals |
US4992445A (en) | 1987-06-12 | 1991-02-12 | American Cyanamid Co. | Transdermal delivery of pharmaceuticals |
US5236689A (en) * | 1987-06-25 | 1993-08-17 | Alza Corporation | Multi-unit delivery system |
US5391381A (en) * | 1987-06-25 | 1995-02-21 | Alza Corporation | Dispenser capable of delivering plurality of drug units |
US5283193A (en) | 1988-06-27 | 1994-02-01 | Asahi Kasei Kogyo K.K. | Process for producing optically active α-substituted organic acid and microorganism and enzyme used therefor |
SE509029C2 (sv) * | 1988-08-16 | 1998-11-30 | Ss Pharmaceutical Co | Långtidsverkande diklofenak-natriumpreparat |
US5202128A (en) | 1989-01-06 | 1993-04-13 | F. H. Faulding & Co. Limited | Sustained release pharmaceutical composition |
US5133974A (en) | 1989-05-05 | 1992-07-28 | Kv Pharmaceutical Company | Extended release pharmaceutical formulations |
AU632602B2 (en) * | 1989-08-02 | 1993-01-07 | John David Arnold | Method and preparation for reducing risk of myocardial infarction |
US5217718A (en) | 1989-08-18 | 1993-06-08 | Cygnus Therapeutic Systems | Method and device for administering dexmedetomidine transdermally |
US5284769A (en) | 1989-10-16 | 1994-02-08 | Chiros Ltd. | Process for preparing a single enantiomer of a lactam using lactamase |
US5362755A (en) | 1990-01-05 | 1994-11-08 | Sepracor, Inc. | Method for treating asthma using optically pure (R)-albuterol |
IE66933B1 (en) * | 1990-01-15 | 1996-02-07 | Elan Corp Plc | Controlled absorption naproxen formulation for once-daily administration |
US5229131A (en) * | 1990-02-05 | 1993-07-20 | University Of Michigan | Pulsatile drug delivery system |
US5158777A (en) * | 1990-02-16 | 1992-10-27 | E. R. Squibb & Sons, Inc. | Captopril formulation providing increased duration of activity |
JPH04234812A (ja) * | 1990-03-16 | 1992-08-24 | Yamanouchi Pharmaceut Co Ltd | 持続性製剤用顆粒 |
JP2558396B2 (ja) * | 1990-06-28 | 1996-11-27 | 田辺製薬株式会社 | 放出制御型製剤 |
US5104899A (en) | 1990-08-13 | 1992-04-14 | Sepracor, Inc. | Methods and compositions for treating depression using optically pure fluoxetine |
US5156850A (en) | 1990-08-31 | 1992-10-20 | Alza Corporation | Dosage form for time-varying patterns of drug delivery |
US5232705A (en) | 1990-08-31 | 1993-08-03 | Alza Corporation | Dosage form for time-varying patterns of drug delivery |
US5422121A (en) | 1990-11-14 | 1995-06-06 | Rohm Gmbh | Oral dosage unit form |
JPH04273816A (ja) * | 1991-02-26 | 1992-09-30 | Tanabe Seiyaku Co Ltd | パルス放出型有核錠 |
ZA923474B (en) * | 1991-05-20 | 1993-01-27 | Marion Merrell Dow Inc | Diltiazem formulation |
US5160744A (en) * | 1991-06-27 | 1992-11-03 | Alza Corporation | Verapmil therapy |
US5326570A (en) * | 1991-07-23 | 1994-07-05 | Pharmavene, Inc. | Advanced drug delivery system and method of treating psychiatric, neurological and other disorders with carbamazepine |
FI93924C (fi) | 1991-09-17 | 1995-06-26 | Martti Lauri Antero Marvola | Menetelmä säädellysti lääkeainetta vapauttavan valmisteen valmistamiseksi |
EP0664118B1 (de) * | 1991-10-04 | 1999-08-25 | Yoshitomi Pharmaceutical Industries, Ltd. | Tablette mit verzögerter freisetzung |
ES2106818T3 (es) * | 1991-10-30 | 1997-11-16 | Glaxo Group Ltd | Composicion multicapa que contiene antagonistas de histamina o secotina. |
US5478577A (en) * | 1993-11-23 | 1995-12-26 | Euroceltique, S.A. | Method of treating pain by administering 24 hour oral opioid formulations exhibiting rapid rate of initial rise of plasma drug level |
US5580578A (en) | 1992-01-27 | 1996-12-03 | Euro-Celtique, S.A. | Controlled release formulations coated with aqueous dispersions of acrylic polymers |
US5223265A (en) | 1992-01-10 | 1993-06-29 | Alza Corporation | Osmotic device with delayed activation of drug delivery |
US5308348A (en) | 1992-02-18 | 1994-05-03 | Alza Corporation | Delivery devices with pulsatile effect |
US5331000A (en) | 1992-03-09 | 1994-07-19 | Sepracor Inc. | Antipyretic and analgesic methods and compositions containing optically pure R(-) ketoprofen |
US5299121A (en) * | 1992-06-04 | 1994-03-29 | Medscreen, Inc. | Non-prescription drug medication screening system |
US5512293A (en) | 1992-07-23 | 1996-04-30 | Alza Corporation | Oral sustained release drug delivery device |
RO116043B1 (ro) | 1992-08-03 | 2000-10-30 | Sepracor Inc | Compozitie farmaceutica |
US5376384A (en) * | 1992-12-23 | 1994-12-27 | Kinaform Technology, Inc. | Delayed, sustained-release pharmaceutical preparation |
JP3091618B2 (ja) | 1993-01-29 | 2000-09-25 | 四郎 小林 | 開環重合法および開環重合用酵素触媒 |
JPH0714056A (ja) * | 1993-06-22 | 1995-01-17 | Matsushita Refrig Co Ltd | 自動販売機の制御装置 |
IL110014A (en) * | 1993-07-01 | 1999-11-30 | Euro Celtique Sa | Solid controlled-release oral dosage forms of opioid analgesics |
JP2916978B2 (ja) * | 1993-08-25 | 1999-07-05 | エスエス製薬株式会社 | 放出開始制御型製剤 |
US5500227A (en) * | 1993-11-23 | 1996-03-19 | Euro-Celtique, S.A. | Immediate release tablet cores of insoluble drugs having sustained-release coating |
JPH08175977A (ja) * | 1994-09-16 | 1996-07-09 | Euro Celtique Sa | アクリル系ポリマーの水性分散液で被覆した放出制御型製剤及びその製法 |
JPH08143476A (ja) * | 1994-11-18 | 1996-06-04 | Japan Tobacco Inc | 薬物放出制御膜及び固形製剤 |
JPH08157392A (ja) * | 1994-12-01 | 1996-06-18 | Kanegafuchi Chem Ind Co Ltd | 放出制御型製剤 |
US5567441A (en) * | 1995-03-24 | 1996-10-22 | Andrx Pharmaceuticals Inc. | Diltiazem controlled release formulation |
IT1276689B1 (it) * | 1995-06-09 | 1997-11-03 | Applied Pharma Res | Forma farmaceutica solida ad uso orale |
CA2222713C (en) * | 1995-07-14 | 2003-04-22 | Andrew John Mcglashan Richards | Composition comprising d-threo-methylphenidate and another drug |
GB9514451D0 (en) | 1995-07-14 | 1995-09-13 | Chiroscience Ltd | Sustained-release formulation |
WO1997003672A1 (en) | 1995-07-14 | 1997-02-06 | Chiroscience Limited | THERAPEUTIC USE OF d-threo-METHYLPHENIDATE |
US5733756A (en) * | 1996-01-05 | 1998-03-31 | Celgene Corporation | Lactams and processes for stereoselective enrichment of lactams, amides, and esters |
US6486177B2 (en) * | 1995-12-04 | 2002-11-26 | Celgene Corporation | Methods for treatment of cognitive and menopausal disorders with D-threo methylphenidate |
US5908850A (en) * | 1995-12-04 | 1999-06-01 | Celgene Corporation | Method of treating attention deficit disorders with d-threo methylphenidate |
US6355656B1 (en) * | 1995-12-04 | 2002-03-12 | Celgene Corporation | Phenidate drug formulations having diminished abuse potential |
US5922736A (en) * | 1995-12-04 | 1999-07-13 | Celegene Corporation | Chronic, bolus administration of D-threo methylphenidate |
US5837284A (en) * | 1995-12-04 | 1998-11-17 | Mehta; Atul M. | Delivery of multiple doses of medications |
US6242464B1 (en) * | 1996-01-22 | 2001-06-05 | Chiroscience Limited | Single isomer methylphenidate and resolution process |
CA2243534C (en) | 1996-02-02 | 2003-08-26 | Medeva Europe Limited | Process for the preparation of d-threo-(r,r)-methylphenidate and recycling of undesired enantiomers by epimerisation |
DK0885191T3 (da) | 1996-03-08 | 2002-05-06 | Medeva Europ Ltd | Opspaltning af threo-methylphenidat |
GB9604943D0 (en) * | 1996-03-08 | 1996-05-08 | Chiroscience Ltd | Resolution |
GB9606417D0 (en) | 1996-03-27 | 1996-06-05 | Chiroscience Ltd | Asymmetric cyclisation |
ATE234602T1 (de) | 1996-08-16 | 2003-04-15 | Alza Corp | Verabreichungsform zur abgabe von steigenden wirkstoffdosen |
ATE321529T1 (de) * | 1996-09-30 | 2006-04-15 | Alza Corp | Dosierungsform für eine verzögerte und zunehmende wirkstoffsfreisetzung |
DK0946151T3 (da) | 1996-11-25 | 2006-08-28 | Alza Corp | Doseringsform med stigende dosisfrigivelse |
GB9700912D0 (en) * | 1997-01-17 | 1997-03-05 | Chiroscience Ltd | Resolution |
US5965734A (en) * | 1997-01-31 | 1999-10-12 | Celgene Corporation | Processes and intermediates for preparing 2-substituted piperidine stereoisomers |
US5936091A (en) * | 1997-05-22 | 1999-08-10 | Celgene Corporation | Processes and intermediates for resolving piperidyl acetamide stereoisomers |
US6962997B1 (en) * | 1997-05-22 | 2005-11-08 | Celgene Corporation | Process and intermediates for resolving piperidyl acetamide steroisomers |
DE69920689T2 (de) | 1998-06-03 | 2005-02-24 | Alza Corp., Mountain View | Vorrichtungen zum Aufrechterhalten eines gewünschten therapeutischen Medikamenteneffekts über einen verlängerten Therapiezeitraum |
IL142896A0 (en) * | 1998-11-02 | 2002-04-21 | Elan Corp Plc | Multiparticulate modified release composition |
US6395752B1 (en) * | 1999-03-04 | 2002-05-28 | Pharmaquest Limited | Method of treating depression using 1-threo-methylphenidate |
US6127385A (en) * | 1999-03-04 | 2000-10-03 | Pharmaquest Limited | Method of treating depression using l-threo-methylphenidate |
CA2366791A1 (en) | 1999-04-06 | 2000-10-12 | Kamal K. Midha | Pharmaceutical dosage form for pulsatile delivery of d-threo-methylphenidate and a second cns stimulant |
US20030170181A1 (en) * | 1999-04-06 | 2003-09-11 | Midha Kamal K. | Method for preventing abuse of methylphenidate |
GB9913458D0 (en) | 1999-06-09 | 1999-08-11 | Medeva Europ Ltd | The therapeutic use of d-threo-methylphenidate |
US6221883B1 (en) * | 2000-04-12 | 2001-04-24 | Ross Baldessarini | Method of dopamine inhibition using l-threo-methylphenidate |
AU2001285325A1 (en) * | 2000-08-28 | 2002-03-13 | Sention, Inc. | Use of threo-methylphenidate compounds to enhance memory |
US20020132793A1 (en) * | 2000-08-28 | 2002-09-19 | Mel Epstein | Use of methylphenidate compounds to enhance memory |
US6344215B1 (en) * | 2000-10-27 | 2002-02-05 | Eurand America, Inc. | Methylphenidate modified release formulations |
US6359139B1 (en) * | 2000-11-07 | 2002-03-19 | Celgene Corporation | Methods for production of piperidyl acetamide stereoisomers |
-
1997
- 1997-07-14 US US08/892,190 patent/US5837284A/en not_active Expired - Lifetime
-
1998
- 1998-03-11 US US09/038,470 patent/US6635284B2/en not_active Expired - Lifetime
- 1998-06-09 DE DE1001772T patent/DE1001772T1/de active Pending
- 1998-06-09 JP JP50716699A patent/JP2002510318A/ja not_active Withdrawn
- 1998-06-09 DE DE69831869T patent/DE69831869T2/de not_active Expired - Lifetime
- 1998-06-09 EP EP05075103A patent/EP1541147A1/de not_active Withdrawn
- 1998-06-09 EP EP05076618A patent/EP1607093A1/de not_active Withdrawn
- 1998-06-09 AT AT98926529T patent/ATE306266T1/de active
- 1998-06-09 WO PCT/US1998/012057 patent/WO1999003471A1/en active IP Right Grant
- 1998-06-09 AU AU78343/98A patent/AU738744B2/en not_active Expired
- 1998-06-09 ES ES98926529T patent/ES2153338T3/es not_active Expired - Lifetime
- 1998-06-09 EP EP98926529A patent/EP1001772B1/de not_active Expired - Lifetime
- 1998-06-09 DK DK98926529T patent/DK1001772T3/da active
- 1998-06-11 CA CA002240329A patent/CA2240329C/en not_active Expired - Lifetime
-
2003
- 2003-06-10 US US10/458,451 patent/US7431944B2/en not_active Expired - Fee Related
-
2005
- 2005-10-25 HK HK05109482A patent/HK1077501A1/xx unknown
-
2010
- 2010-07-09 JP JP2010157017A patent/JP5412700B2/ja not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
US5837284A (en) | 1998-11-17 |
ES2153338T3 (es) | 2006-04-16 |
CA2240329A1 (en) | 1999-01-14 |
DE69831869T2 (de) | 2006-07-13 |
AU738744B2 (en) | 2001-09-27 |
ES2153338T1 (es) | 2001-03-01 |
JP2002510318A (ja) | 2002-04-02 |
EP1001772A4 (de) | 2002-10-30 |
JP5412700B2 (ja) | 2014-02-12 |
DK1001772T3 (da) | 2006-02-20 |
JP2010265299A (ja) | 2010-11-25 |
EP1001772A1 (de) | 2000-05-24 |
EP1001772B1 (de) | 2005-10-12 |
EP1607093A1 (de) | 2005-12-21 |
HK1077501A1 (en) | 2006-02-17 |
EP1541147A1 (de) | 2005-06-15 |
WO1999003471A1 (en) | 1999-01-28 |
DE69831869D1 (de) | 2006-02-23 |
AU7834398A (en) | 1999-02-10 |
US20030113373A1 (en) | 2003-06-19 |
US6635284B2 (en) | 2003-10-21 |
US7431944B2 (en) | 2008-10-07 |
US20040091532A1 (en) | 2004-05-13 |
CA2240329C (en) | 2004-12-28 |
ATE306266T1 (de) | 2005-10-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE1001772T1 (de) | Verbesserte verabreichungstechnik für multiple medikamentengaben | |
NO20053105D0 (no) | Oral, analgesisk doseringsform med forlenget frigivelse for administrering ±n gang pr. dag. | |
ES2170069T3 (es) | 1-alfa-hidroxiprevitamina d para administracion oral. | |
CY1111088T1 (el) | Θεραπευτικη φαρμακοτεχνικη μορφη για χορηγηση τολτεροδινης με ελεγχομενη απελευθερωση | |
WO2005065069A3 (en) | Pharmaceutical methods, dosing regimes and dosage forms for the treatment of alzheimer's disease | |
ATE277594T1 (de) | Vorrichtungen um eine verlängerte medikamententherapie zu erreichen | |
ES2162615T3 (es) | Metodo para tratar o prevenir diabetes de tipo 1 mediante la administracion oral de insulina. | |
NO971206D0 (no) | Forlenget-frigjöringsformulering | |
CY1105707T1 (el) | Συνδυασμοι φορμοτερολης και ενος αλατος τριοτροπιου | |
NO20022014L (no) | En fast oral kontrollert frigjorende doseringsform inneholdende hydrokodon | |
GEP20033014B (en) | Enteric Coated Pharmaceutical Composition and Method of Manufacturing | |
HK1001960A1 (en) | Method, compositions and kits for increasing the oral bioavailability of pharmaceutical agents | |
PT957899E (pt) | Forma de dosagem para proporcionar um medicamento numa dose crescente | |
HK1045113A1 (zh) | 給予固定的曲馬朵和雙氯酚酸組合的口服給藥形式 | |
NO994165L (no) | Anvendelse av deskarboetoksyloratadin for fremstilling av et medikament for behandling av urininkontinens, reisesyke og svimmelhet | |
HUP0204391A2 (en) | The use of mirtazapine for the preparation of pharmaceutical composition suitable for the treatment of sleep disorders | |
ES2053683T3 (es) | Forma de medicamento de aplicacion oral para el tratamiento de la hipertension una vez al dia con hidrocloruro de diltiazem. | |
GB9420748D0 (en) | 1,5 benzodiazepine derivatives | |
PT942729E (pt) | Utilizacao de antagonistas de receptores nk-1 para tratamento de doencas do stresse | |
HUP0104941A2 (hu) | Több gyógyszerformát tartalmazó bliszter | |
IT1271354B (it) | Preparazione di una forma farmaceutica atta a combattere l'iperinsulinismo contenente n-acetil cisteine e loro analoghi | |
UA36137A (uk) | Спосіб лікування хворих на хронічне легеневе серце | |
DK0615446T3 (da) | Retard-lægemiddel indeholdende et dihydropyridinderivat i nanosolform og fremstilling heraf |